Vitamin D3 + K2 for longevity
Grade AFoundational fat-soluble vitamin pair: D3 regulates calcium homeostasis and immune function; K2 directs that calcium into bone rather than soft tissue.
Foundational fat-soluble vitamin pair: D3 regulates calcium homeostasis and immune function; K2 directs that calcium into bone rather than soft tissue.
D3 (cholecalciferol) converts to calcitriol and acts on the VDR to regulate hundreds of genes including immune, bone, and cardiovascular pathways. K2 (MK-7) activates matrix Gla-protein and osteocalcin to traffic calcium into bone and out of arterial walls.
Vitamin D3 + K2 is typically taken orally as softgel with carrier oil (mct or olive), with largest fatty meal. D3 (cholecalciferol) converts to calcitriol and acts on the VDR to regulate hundreds of genes including immune, bone, and cardiovascular pathways. K2 (MK-7) activates matrix Gla-protein and osteocalcin to traffic calcium into bone and out of arterial walls. Effective range is 1,000–10,000 IU D3 (titrate to serum 25-OH-D 40–70 ng/mL), with 2,000–5,000 IU D3 + 100–200 mcg K2 (MK-7) being the most-studied dose. Taking it with food improves absorption and reduces GI upset.
Timing (With largest fatty meal) is chosen to match the compound's pharmacokinetics and the physiological pathway it targets. Consistency matters more than the exact hour.
Grade A — multiple randomised human trials or meta-analyses support the primary claim. Dosing, mechanism and safety are well characterised in humans.
The primary references used to grade Vitamin D3 + K2 are listed below. Cross-check against the current literature and expect the grade to move as new human trials publish.
Further reading: Research library → · Protocols →
Common questions about dose, benefits, side effects and longevity use of Vitamin D3 + K2.
2,000–5,000 IU D3 + 100–200 mcg K2 (MK-7) is the most-studied dose, with a full effective range of 1,000–10,000 IU D3 (titrate to serum 25-OH-D 40–70 ng/mL). Take it with largest fatty meal, with food.
D3 (cholecalciferol) converts to calcitriol and acts on the VDR to regulate hundreds of genes including immune, bone, and cardiovascular pathways. K2 (MK-7) activates matrix Gla-protein and osteocalcin to traffic calcium into bone and out of arterial walls.
Subjective effects can appear in 1–3 weeks. Objective biomarker shifts typically require 8–12 weeks of consistent dosing, which is why baseline and 12-week labs are recommended.
Yes — Vitamin D3 + K2 is best taken with a meal containing some fat to maximise absorption and reduce GI upset.
Hypercalcemia at chronically excessive D3 doses (>10,000 IU sustained). Avoid in: Sarcoidosis or other granulomatous disease, Hyperparathyroidism.
Most users run Vitamin D3 + K2 continuously and reassess every 12 weeks. A short wash-out can restore responsiveness if effects plateau. Long-term dosing should be paired with periodic bloods.
Commonly stacked with: Magnesium glycinate, Omega-3, Boron. Introduce one compound at a time to preserve attribution of effect and side effect.
Look for third-party testing (NSF, Informed Sport, USP), a standardised active compound on the label, a clear country of origin, and dose-per-serving that matches the researched range.
| Attribute | Vitamin D3 + K2This page | Glucosamine | Taurine |
|---|---|---|---|
| Evidence | Grade A88/100 | Grade B62/100 | Grade C42/100 |
| Category | Longevity | Longevity | Longevity |
| Best for | Maintains serum 25-OH-D in the optimal 40–70 ng/mL range | 15% lower all-cause mortality in a 495,077-person prospective cohort | Extended lifespan in mice and worms, and improved healthspan markers in monkeys |
| Typical dose | 2,000–5,000 IU D3 + 100–200 mcg K2 (MK-7) | 1,500 mg daily | 1-3 g daily |
| Timing | With largest fatty meal | With food, split into two or three doses if it upsets your stomach | Any time; split doses if taking above 3 g |
| Form | Softgel with carrier oil (MCT or olive) | Glucosamine sulphate is the form used in most positive trials; hydrochloride has weaker support | Powder (cheapest by far) or capsule |
| Action | Current page | View → | View → |